Skip to main content
. Author manuscript; available in PMC: 2013 Jan 3.
Published in final edited form as: J Clin Oncol. 2009 May 26;27(23):3742–3748. doi: 10.1200/JCO.2008.20.0642

Fig 1.

Fig 1

Changes in prostate-specific antigen (PSA) with abiraterone acetate. Waterfall plot showing maximal percentage change in PSA from baseline with single-agent abiraterone acetate 1,000 mg at (A) 12 weeks and (B) any time point after 12 weeks. The dashed lines indicate PSA declines of 30%, 50%, and 90%.